Literature DB >> 6443770

Treatment of invasive external otitis with cefsulodin.

M H Mendelson, B R Meyers, S Z Hirschman, E R Shapiro, S C Parisier.   

Abstract

Thirteen patients with invasive infections of the external ear were treated with cefsulodin sodium. Eleven were elderly diabetic patients with malignant external otitis, and two were nondiabetic adults with cellulitis or chondritis of the external ear. Four of 11 patients with malignant external otitis had extensive disease, with progression of infection to the petrous apex, medial base of the skull, or parapharyngeal soft tissue. Eleven patients had granulation tissue in the external auditory canal, and three presented with cranial nerve palsies (V, VII, IX, X). Pseudomonas aeruginosa was isolated from all patients. Minimal inhibitory concentrations of cefsulodin for the strains isolated were 1.56-6.25 micrograms/ml (mean, 3.37 microliter/ml) and minimal bactericidal concentrations were 1.56-25 micrograms/ml (mean, 5.59 micrograms/ml). Duration of therapy was from one to 12 weeks. Nine patients had a positive clinical response, three had recurrent disease after initial improvement, and one was lost to follow-up. A positive response was correlated with a longer duration of therapy and less extensive disease; complications were minor. Cefsulodin appears to be an effective agent for the treatment of selected patients with invasive external otitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6443770     DOI: 10.1093/clinids/6.supplement_3.s698

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  2 in total

1.  Granulation tissue concentrations of ofloxacin after oral administration in invasive external otitis.

Authors:  M Z Himmelfarb; D Zikk; Y Rapoport; C Redianu; I Shalit
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 2.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.